- Home
- ETHZ vs PROK Comparison
ETHZ vs PROK Comparison
Compare ETHZ & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETHZ
- PROK
- Stock Information
- Founded
- ETHZ N/A
- PROK 2015
- Country
- ETHZ United States
- PROK United States
- Employees
- ETHZ N/A
- PROK N/A
- Industry
- ETHZ Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETHZ Health Care
- PROK Health Care
- Exchange
- ETHZ Nasdaq
- PROK Nasdaq
- Market Cap
- ETHZ 465.0M
- PROK 384.2M
- IPO Year
- ETHZ N/A
- PROK N/A
- Fundamental
- Price
- ETHZ $2.31
- PROK $2.25
- Analyst Decision
- ETHZ
- PROK Buy
- Analyst Count
- ETHZ 0
- PROK 5
- Target Price
- ETHZ N/A
- PROK $6.25
- AVG Volume (30 Days)
- ETHZ 30.2M
- PROK 1.7M
- Earning Date
- ETHZ 10-26-2025
- PROK 08-12-2025
- Dividend Yield
- ETHZ N/A
- PROK N/A
- EPS Growth
- ETHZ N/A
- PROK N/A
- EPS
- ETHZ N/A
- PROK N/A
- Revenue
- ETHZ N/A
- PROK $527,000.00
- Revenue This Year
- ETHZ N/A
- PROK $265.05
- Revenue Next Year
- ETHZ N/A
- PROK N/A
- P/E Ratio
- ETHZ N/A
- PROK N/A
- Revenue Growth
- ETHZ N/A
- PROK N/A
- 52 Week Low
- ETHZ $0.66
- PROK $0.46
- 52 Week High
- ETHZ $17.75
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- ETHZ N/A
- PROK 43.80
- Support Level
- ETHZ N/A
- PROK $2.23
- Resistance Level
- ETHZ N/A
- PROK $2.56
- Average True Range (ATR)
- ETHZ 0.00
- PROK 0.16
- MACD
- ETHZ 0.00
- PROK -0.02
- Stochastic Oscillator
- ETHZ 0.00
- PROK 9.33
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.